medigraphic.com

2016, Number 1

<< Back Next >>

Med Sur 2016; 23 (1)

Poor survival in triple negative breast cancer

Tapia-Salas I, Motola-Kuba D, Chable-Montero F, Alvarado-Luna G, Arrieta-Rodriguez Ó

Language: English
References: 12
Page: 34-37
PDF size: 103.06 Kb.


ABSTRACT

Background. Triple negative breast cancer (TNBC) refers to the absence of expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor-2. This identification helps to determine prognosis and treatment of breast cancer. The aim of this work was to determine the prevalence of triple negative breast cancer patients in our institution and to determine survival compared to non-triple negative breast cancer patients. Material and methods. It is a retrospective study from clinical records between January 1995 and December 2014. Our analysis included women who were diagnosed with invasive breast cancer, from whom we obtained clinical, pathologic and immunohistochemical variables. Survival between triple negative breast cancer patients and non-triple negative breast cancer (NTNBC) patients was compared. Results. In total, 534 patients with a breast cancer diagnosis were included. TNBC was diagnosed in 16.1% of patients. Median overall survival (OSR) was 131 months in TNBC (95% CI, 8.4-13.4), and 160.3 months in NTNBC (95% CI, 11.6- 15.1, P = 0.0007). Conclusion. Prevalence of TNBC was lower in our population than reported in other countries and in other Mexican population. TNBC patients have lower survival rates than NTNBC patients.


REFERENCES

  1. INEGI. Available at: http://www.inegi.org.mx/saladeprensa/aproposito/ 2015/mama0.pdf.

  2. Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet 2016; 293: 247-69.

  3. Burnett JP, Korkaya H, Ouzounova MD, Jiang H, Conley SJ, Newman BW, et al. Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options. Sci Rep 2015; 5: 15821.

  4. Kaminska M, Ciszewski T, Lopacka-Szatan K, Miotla P, Staroslawska E. Breast cancer risk factors. Prz Menopauzalny 2015; 14: 196-202.

  5. Marme F, Schneeweiss A. Targeted therapies in triple-negative breast cancer. Breast Care (Basel) 2015; 10: 159-66.

  6. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 2011; 117: 3658-69.

  7. Qiu J, Xue X, Hu C, Xu H, Kou D, Li R, et al. Comparison of clinicopathological features and prognosis in triple-negative and non-triple negative breast cancer. J Cancer 2016; 7: 167-73.

  8. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selectio

  9. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009; 20: 1071-82.

  10. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-48.

  11. Chen DR, Lin C, Wang YF. Window of opportunity: A new insight into sequential bevacizumab and paclitaxel in two cases of metastatic triple-negative breast cancer. Exp Ther Med 2015; 10: 885-8.

  12. Nakatsukasa K, Koyama H, Oouchi Y, et al. Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2- negative primary breast cancer. Breast Cancer 2016: Epub ahead of print.




2020     |     www.medigraphic.com